Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates for brain health disorders, and its filings offer detailed information on clinical progress, financing transactions and corporate matters.
Through Forms 8‑K, MindMed reports material events such as underwritten public offerings of common shares under its shelf registration statement on Form S‑3, entry into underwriting agreements, and the intended use of proceeds to fund research and development, working capital and general corporate purposes. Other 8‑K filings describe the release of quarterly financial results, updated corporate presentations, and announcements related to clinical and scientific milestones, including publication of MM120 trial data in generalized anxiety disorder.
MindMed’s filings also identify its jurisdiction of incorporation in British Columbia, Canada, its listing of common shares on The Nasdaq Stock Market LLC under the symbol MNMD, and its status as an emerging growth company. Investors can use this page to review prospectus supplements, opinions and exhibits referenced in 8‑K filings, as well as periodic reports such as Forms 10‑K and 10‑Q accessed via EDGAR.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as the terms of public offerings, changes in cash and investments, and updates on the development of MM120 and MM402. Real-time updates from EDGAR, along with structured access to Forms 10‑K, 10‑Q and 4, help users quickly locate information on MindMed’s financial condition, capital structure and insider-related disclosures.
Definium Therapeutics, Inc.7.2% of the company as of December 31, 2025. This position includes 2,000,000 common shares plus 5,428,775 shares that can be acquired through a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 98,509,279 common shares reported outstanding as of October 31, 2025, plus the warrant shares. The filing is made jointly by Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz, who certify that the securities are not held for the purpose of changing or influencing control of the issuer. The issuer recently changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a new significant ownership position in Definium Therapeutics, Inc. They beneficially own 5,000,000 Common Shares, representing 5.08% of the class, with sole voting and dispositive power over these shares.
The ownership percentage is based on 98,509,279 Common Shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The investors state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Definium Therapeutics, Inc. received an amended Schedule 13G from Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin reporting a significant ownership position. The group reports beneficial ownership of 5,676,540 common shares, representing 5.54% of the class as of December 31, 2025.
This total includes 4,000,000 pre-funded warrants exercisable into common shares, calculated against 102,509,279 shares (98,509,279 shares outstanding as of October 31, 2025 plus the warrant shares). The warrants are subject to a 9.99% Maximum Percentage cap on post-exercise ownership, limiting how many can be exercised at any time.
The reporting persons state that the securities were not acquired to change or influence control, indicating a passive investment intent under the relevant SEC rules.
Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.
The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.
Definium Therapeutics, Inc. reported a change to its board of directors. On January 28, 2026, the board expanded from six to seven members and appointed Roger Adsett as a director effective January 29, 2026, with a term running until the 2026 annual general meeting, or until a successor is chosen or he departs earlier.
Adsett was not assigned to any board committees at this time. Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $40,000, paid quarterly on a pro-rata basis. He also received an option to purchase 50,000 common shares, vesting one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to continued board service.
The option grant was issued under the company’s 2025 Equity Incentive Plan. The filing notes there are no special arrangements leading to his appointment and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., reported estimated preliminary cash, cash equivalents and investments of about $412 million as of December 31, 2025, shared in a corporate presentation posted online. This figure is unaudited, may change, and has not been reviewed or examined by KPMG LLP.
The company has officially changed its corporate name to Definium Therapeutics, Inc., with board approval and updated British Columbia corporate records. The rebranding is described as aligning with its next phase as a psychiatric drug development leader. Common shares will keep the same CUSIP and begin trading on the Nasdaq under the new ticker “DFTX” starting January 13, 2026, with no action required from shareholders.
Mind Medicine (MindMed) Inc. (MNMD) reported Q3 results and liquidity updates. The company recorded a net loss of $67.3 million for the quarter, driven by operating expenses of $45.7 million (research and development $31.0 million; general and administrative $14.7 million) and a $22.5 million non-cash loss from the change in fair value of 2022 USD Financing Warrants. Basic and diluted net loss per share were $0.78.
As of September 30, 2025, cash and cash equivalents were $19.96 million and short-term investments were $189.11 million. Total assets were $236.9 million against total liabilities of $106.3 million, resulting in shareholders’ equity of $130.6 million. Common shares outstanding were 76,774,057 as of quarter-end; 98,509,279 were outstanding as of October 31, 2025.
Subsequent to quarter-end, on October 31, 2025, the company closed an underwritten public offering for gross proceeds of $258.9 million (net $242.8 million) to fund product development and general purposes. Earlier in 2025, MindMed amended its K2 HealthVentures credit facility, funded $42.0 million in a first tranche, and saw $1.0 million converted into 249,377 common shares.
Mind Medicine (MindMed) Inc. (MNMD) furnished an update via an 8-K announcing it issued a press release with financial results for its second quarter ended September 30, 2025, including information about a conference call to discuss the results and recent corporate highlights.
The company also posted an updated corporate presentation on its website. The press release is provided as Exhibit 99.1, and the presentation as Exhibit 99.2.
Mind Medicine (MindMed) Inc. (MNMD) announced an underwritten public offering of 18,375,000 common shares at $12.25 per share. Underwriters were granted a 30‑day option to buy up to 2,756,250 additional shares at the same price, which was exercised in full on October 30, 2025. Gross proceeds are expected to be approximately $258.9 million, with estimated net proceeds of $242.8 million after discounts and expenses. The offering is expected to close on October 31, 2025.
The company plans to use net proceeds to fund research and development of its product candidates, as well as for working capital and general corporate purposes. A portion may be used for potential investments or acquisitions, though there are no current agreements. Directors and executive officers agreed to a 90‑day lock‑up. The offering was made under MindMed’s effective shelf registration statement on Form S‑3 with a base prospectus and prospectus supplement.